TMCI Stock News: Robbins LLP Reminds Treace Medical Concepts, Inc. Stockholders That They Can Lead the Class Action Lawsuit

Group 1 - The class action was filed on behalf of all persons and entities that purchased Treace Medical Concepts, Inc. (TMCI) securities between May 8, 2023, and May 7, 2024 [1] - The company focuses on advancing the standard of care for the surgical management of bunion and related midfoot deformities [1] - Allegations include that Treace Medical misled investors regarding the demand for its primary product, the Lapiplasty 3D Bunion Correction System, and that competition impacted its demand [2] Group 2 - The complaint states that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [2] - Following the revelation of these issues, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2] - Shareholders interested in serving as lead plaintiff must file their papers with the court by June 10, 2025 [3] Group 3 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]